Fulgent Genetics

We're excited to announce a significant expansion of Fulgent's cardiovascular test menu. The update spans cardiomyopathy, arrhythmia, lipid disorders, and more, with 99 newly added genes on our Comprehensive Cardiovascular NGS Panel (now 363 genes total) and a brand-new Comprehensive Dyslipidemia Panel.

A few of the updated panels:

🔶 Comprehensive Cardiovascular NGS Panel: 363 genes
🔶 Comprehensive Cardiomyopathy Panel: 172 genes
🔶 Long QT/Brugada Syndrome Panel: 36 genes
🔶 Comprehensive Dyslipidemia Panel: 34 genes (new)
🔶 Atrial Fibrillation Panel: 28 genes
🔶 Familial Hypercholesterolemia Panel: 10 genes

As with most Fulgent tests, each one can be tailored to a focused subset of genes to fit the clinical needs of individual patients.

Learn more at https://www.fulgentgenetics.com/products/disease/cardiovascular.html

Heading to in Chicago?

Fulgent will be exhibiting and connecting with teams advancing clinical oncology programs from translational research through trial ex*****on. We offer global support from the US, Australia, and China in CLIA-certified and CAP-accredited laboratories.

For groups building or scaling biomarker strategies, we support clinically relevant oncology workflows including:

• Solid tumor NGS molecular profiling (DNA+RNA) with key IO biomarkers like MSI and TMB
• Liquid biopsy / ctDNA profiling for solid tumors
• Heme NGS panels and specialized hematopathology testing
• HRR/HRD molecular profiling and germline hereditary cancer testing
• IHC/FISH and cytogenetics to complement NGS readout

Stop by booth #11094 or reach out to [email protected] beforehand to connect!

The latest findings on the efficacy of Fulgent's nano-encapsulated anti-tumor drug FID-007 will be presented at this year's American Society of Clinical Oncology (ASCO) meeting.

We're proud to announce that our abstract, “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)”, will be featured at the Head and Neck Cancer Track of the ASCO rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago.

The Phase 2 study is designed to evaluate the efficacy of different dosing regimens as well as to characterize the pharmacokinetics (PK) and safety and tolerability of FID-007 in combination with cetuximab in patients with disease progression after treatment with PD-L1-based immune checkpoint inhibitor.

https://www.businesswire.com/news/home/20260422182838/en/Fulgent-Selected-to-Present-Rapid-Oral-Abstract-Within-the-Head-and-Neck-Cancer-Track-Session-at-the-2026-ASCO-Annual-Meeting